Welcome to our dedicated page for Kala Pharmaceuticals news (Ticker: KALA), a resource for investors and traders seeking the latest updates and insights on Kala Pharmaceuticals stock.
KALA BIO, Inc. (NASDAQ: KALA) generates news that spans clinical trial developments, strategic reviews, financing transactions and capital structure changes in the ophthalmology-focused biopharmaceutical space. As a clinical-stage company centered on rare and severe eye diseases, its updates often revolve around the progress and outcomes of its investigational programs and the funding required to support them.
A major theme in recent KALA news has been the development of KPI-012, a human mesenchymal stem cell secretome (MSC-S) therapy studied for persistent corneal epithelial defect (PCED). The company has reported on milestones such as completion of enrollment in the CHASE Phase 2b trial and, later, topline results showing that the study did not meet its primary or key secondary endpoints. These disclosures were accompanied by announcements about ceasing development of KPI-012 and the MSC-S platform, workforce reductions and an evaluation of strategic options.
Another significant stream of news involves financing and restructuring. KALA has issued press releases on a registered direct offering of common stock, a securities purchase agreement for non-voting convertible preferred stock, and a convertible loan agreement, as well as updates on a loan settlement with Oxford Finance LLC that resolved substantial debt obligations. Leadership and governance changes, including appointments in executive roles and board positions, have also been reported.
Investors and followers of KALA BIO’s news can expect coverage related to clinical data readouts, regulatory designations, Nasdaq listing compliance matters, debt settlements, equity offerings and strategic transaction discussions. Monitoring this news flow provides context on the company’s evolving pipeline priorities, financial position and potential corporate actions. For an ongoing view of these developments, readers can review the chronological news feed associated with the KALA ticker.
Kala Pharmaceuticals announced the granting of non-statutory stock options to new employees as inducement awards under Nasdaq Listing Rule 5635(c)(4). A total of 131,500 shares were granted to three new employees following the acquisition of Combangio, including 100,000 shares to Darius Kharabi, the new Chief Business Officer. The options have an exercise price of $2.10 per share and a ten-year term, with vesting over four years. These steps align with the company’s ongoing focus on innovative therapies for eye diseases.
Kala Pharmaceuticals reported $3.1 million in net revenue for Q3 2021, up from a year earlier, with EYSUVIS prescriptions rising by 19% compared to Q2 2021. The company has expanded its pipeline through the acquisition of Combangio, focusing on KPI-012, for treating rare ocular surface diseases. However, the net loss for Q3 2021 was $28.1 million or $0.43 per share, slightly higher than the $27.9 million loss in Q3 2020. The financial outlook expects operational funding through Q2 2023, considering ongoing revenue generation and cost containment strategies.
Kala Pharmaceuticals has acquired Combangio, a clinical-stage company, to enhance its pipeline for severe ocular surface diseases. The acquisition includes KPI-012, a promising therapy for persistent corneal epithelial defect (PCED). The Phase 1b trial showed positive results, with six out of eight patients achieving complete healing. Kala plans to submit an IND application to the FDA and initiate a Phase 2/3 trial in 3Q 2022. Mark S. Blumenkranz joins Kala's Board of Directors as part of this strategic move, expected to strengthen its offerings in eye health.
Kala Pharmaceuticals (NASDAQ:KALA) has rescheduled its financial results conference call to report Q3 2021 results on November 15 at 10:30 AM ET. The call will provide a business update, with access available via dial-in or a live webcast on the company's investor site. Kala focuses on innovative therapies for eye diseases, featuring products like EYSUVIS and INVELTYS, utilizing the AMPPLIFY Drug Delivery Technology. For further details, visit their website.
Kala Pharmaceuticals, Inc. (NASDAQ:KALA) has announced its participation in two upcoming virtual healthcare investor conferences in November 2021. The Jefferies London Healthcare Conference will feature a pre-recorded fireside chat available on November 18, 2021, starting at 3:00 am ET. Additionally, management will engage in a virtual fireside chat at Ophthalmology Day at BTIG on November 30, 2021, at 10:00 am ET. Kala is known for its innovative therapies for eye diseases, including EYSUVIS® and INVELTYS®. For more details, visit kalarx.com.
Kala Pharmaceuticals, Inc. (NASDAQ:KALA) will report its third quarter 2021 financial results on November 15, 2021. A conference call is scheduled for 8:30 a.m. ET to discuss these results and provide a business update. The company focuses on developing innovative therapies for eye diseases using its AMPPLIFY® mucus-penetrating particle Drug Delivery Technology. Its key products include EYSUVIS® for dry eye disease and INVELTYS® for post-operative inflammation following ocular surgery. Further details and the live webcast are available on Kala's website.
Kala Pharmaceuticals (NASDAQ: KALA) announced the grant of non-statutory stock options to ten new employees as inducement awards apart from its 2017 Equity Incentive Plan, complying with NASDAQ Listing Rule 5635(c)(4). The options, totaling 70,000 shares, were granted on October 18, 2021, with an exercise price of $1.85 per share. The options have a ten-year term and vest over four years, with 25% vesting after the first year. This move aims to attract and retain talent while aligning employee incentives with shareholder interests.
Kala Pharmaceuticals (NASDAQ: KALA) has appointed C. Daniel Myers to its Board of Directors as a Class III director. With over 35 years in ophthalmic pharmaceuticals, Myers will contribute to the Compensation and Nominating Committees. CEO Mark Iwicki expressed optimism about Myers' extensive background, emphasizing its potential to enhance Kala's commercial strategies, particularly for its products EYSUVIS and INVELTYS. Concurrently, Rajeev Shah will step down from the Board after significant contributions since 2015, marking a leadership transition for the company.
Kala Pharmaceuticals, Inc. (NASDAQ:KALA) announced the granting of non-statutory stock options to eleven new employees, totaling 112,000 shares, as inducement awards compliant with NASDAQ Listing Rule 5635(c)(4). The options granted on September 15, 2021, have an exercise price of $3.08 per share, matching the closing price on that date. The awards vest over four years, with 25% vested after the first year and the remainder vesting monthly. The initiative aims to attract talent in the biopharmaceutical sector focused on innovative ocular therapies.
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company specializing in ocular therapies, announced participation in two virtual healthcare investor conferences in September 2021. The H.C. Wainwright 23rd Annual Global Investment Conference will feature a pre-recorded presentation available from September 13 at 7:00 a.m. ET. Additionally, the Cantor Global Healthcare Conference 2021 will have a presentation starting September 28 at 4:40 p.m. ET. Both events will allow for virtual one-on-one meetings. Archived recordings will be accessible on the company's website for at least 30 days.